About

This information provides supporting context for the Tasigna (nilotinib) Dose Calculator. Nilotinib is a tyrosine kinase inhibitor (TKI) indicated for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Proper dosing is critical for efficacy and safety, with distinct considerations for adult and pediatric populations, as well as specific clinical scenarios requiring dose adjustments.

Outputs

The calculator provides the following key outputs for initial dosing guidance:

  • Single Dose: The recommended amount of nilotinib in milligrams (mg) to be taken at one time.
  • Dosing Schedule: The frequency of administration, which is typically twice daily (BID).
  • Total Daily Dose: The combined total amount of nilotinib taken over a 24-hour period.
  • Dispensing Guidance: A suggested combination of available capsule strengths (50 mg, 150 mg, 200 mg) to achieve the single dose.
  • Body Surface Area (BSA): For pediatric patients, the calculated BSA in m², which is used to determine the appropriate dose.

How to Use

To determine the recommended initial dose, follow these steps:

  1. Select Patient Population: Choose between "Adult (≥ 18 years)" or "Pediatric (1 to < 18 years)".
  2. Select Indication: Choose the appropriate clinical reason for treatment (e.g., "Newly diagnosed Ph+ CML-CP").
  3. Enter Pediatric Data: If "Pediatric" is selected, input the patient's weight in kilograms (kg) and height in centimeters (cm) to enable BSA calculation.
  4. Calculate Dose: The tool will compute the dose based on the provided inputs.

Dosing Overview

The standard dosing for Tasigna varies by indication and patient population:

  • Newly Diagnosed Ph+ CML-CP (Adults): 300 mg twice daily.
  • Resistant or Intolerant Ph+ CML (Adults): 400 mg twice daily.
  • Pediatric Ph+ CML-CP: 230 mg/m² twice daily, rounded to the nearest 50 mg. The single dose should not exceed 400 mg.

Administration: Tasigna must be taken on an empty stomach. No food should be consumed for at least 2 hours before the dose and for at least 1 hour after the dose. Capsules should be swallowed whole with water.

Switching

Patients with CML who are resistant or intolerant to prior therapy, including imatinib, may be switched to nilotinib. The recommended starting dose in this setting is 400 mg twice daily. Clinical monitoring, including assessment for potential toxicities and response to therapy, is crucial after switching treatments.

Missed Dose

If a dose is missed, the patient should not take an additional dose. They should take the next usual prescribed dose at its regular time. Doubling the dose to make up for a missed one should be avoided.

Safety Alerts

Tasigna carries a boxed warning for QT prolongation and sudden deaths. An ECG should be performed at baseline, seven days after initiation, and periodically thereafter. Hypokalemia or hypomagnesemia must be corrected prior to and during therapy. Concomitant use with drugs known to prolong the QT interval and strong CYP3A4 inhibitors should be avoided.

Other significant risks include myelosuppression, pancreatitis (elevated serum lipase), hepatotoxicity, and fluid retention. Consult the full prescribing information for a complete list of warnings and precautions.

FAQ

1. Why is the pediatric dose based on body surface area (BSA)?

BSA-based dosing is common in pediatric oncology to account for differences in drug metabolism and distribution related to body size, providing a more accurate dose than weight-based calculations alone.

2. What is the maximum single dose for a pediatric patient?

The maximum single dose for a pediatric patient is capped at 400 mg, even if their BSA calculation results in a higher theoretical dose.

3. What happens if the calculated pediatric dose is not a multiple of 50 mg?

The calculator automatically rounds the calculated dose (230 mg/m²) to the nearest 50 mg to allow for practical administration using available capsule strengths.

4. Why must Tasigna be taken on an empty stomach?

Food, particularly high-fat meals, can significantly increase the absorption of nilotinib, leading to higher drug levels in the blood and an increased risk of toxicity, including life-threatening QT prolongation.

5. Can the capsules be opened for patients who cannot swallow them?

Yes. For patients with difficulty swallowing, the contents of the capsule can be mixed with one teaspoon of applesauce and must be taken immediately. This mixture should not be stored.

6. Does the calculator provide guidance for renal impairment?

No, the tool does not provide specific adjustments for renal impairment. While clinical studies suggest no significant change in nilotinib pharmacokinetics in patients with renal impairment, clinicians should consult the prescribing information and use clinical judgment.

7. How is hepatic impairment defined for dose reduction?

The tool uses the Child-Pugh classification. Moderate impairment corresponds to Child-Pugh B, and severe impairment corresponds to Child-Pugh C, both of which require a reduced starting dose.

8. What should I do if a patient must take a strong CYP3A4 inhibitor?

If concomitant use is unavoidable, a dose reduction of Tasigna is recommended (e.g., to 150 mg once daily). Close monitoring for QTc prolongation is essential. The dose should be adjusted back up after the inhibitor is discontinued.

References

  1. Tasigna (nilotinib) US Prescribing Information. Novartis Pharmaceuticals Corporation. Updated September 2023. Accessed via FDA.gov.
  2. Tasigna (nilotinib) European Summary of Product Characteristics (SmPC). European Medicines Agency.
  3. Tasigna Official Healthcare Professional Site. Novartis.
  4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Myeloid Leukemia. National Comprehensive Cancer Network. (Version 2.2024).
PRO
Ad-Free Access
$3.99 / month
  • ✓ No Interruptions
  • ✓ Faster Page Loads
  • ✓ Support Content Creators
Subscribe Now